% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • lipo928 lipo928 Apr 28, 2013 9:05 AM Flag



    Galena is a biopharmaceutical company, involved in the development of oncology treatments. The company’s leading candidate is NeuVax which is currently in Phase III trials for treating the recurrence of breast cancer. In the last 52 weeks the company stock has fluctuated between $1.04 and $2.6. Right now there is a very high demand for small biotechnology companies with promising drug candidates. This is because a number of major patents are expiring, such as Lipitor and Seroquel IR which means that manufacturers of these companies are being forced to invest in new drugs to fill this major void.

    Galena has a very strong recommendation from sell side analysts which have unanimous buy rating on the stock. The mean sell side target price on the stock is $4.8 which is 50% above the current stock price. The stock can more than double at this price if any news of a potential acquisition breaks out. There are number of potential buyers of Galena which includes some leading players like AstraZeneca and Pfizer.

    AstraZeneca has recently decided to focus on three key areas which also include Oncology. Galena would be a perfect fit for a company suffering from a weak pipeline and falling revenues such as AstraZeneca (NYSE: AZN). The company currently has more than $8.5 billion in cash and can easily afford Galena worth approximately $200 million. AstraZeneca has already announced that it plans to make focused acquisitions and Galena will make a lot of sense for the struggling giant.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.3404-0.0046(-1.33%)Sep 27 4:00 PMEDT